Oncology

Wear it Pink
#Breast cancer #Breast Cancer Now #Cancer research #Chemotherapy #Chemotherapy-resistance #Drug discovery #Oncology #Tumours

Five breakthroughs advancing breast cancer therapies

Not only is October Breast Cancer Awareness Month but October 21 is Wear it Pink 2022, Breast Cancer Now’s annual fundraising day. While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US1),… Read More

#Cancer Research #News #Trending News

Flow cytometry
#Cancer #Cancer research #Fibroblasts #Flow Cytometry #Immunology #Oncology #Tumour biology

Flow cytometry technologies and cancer associated fibroblasts

Listen to this article on the DDW podcast: Dr Amber Miller, Flow Cytometry Scientist, Fortis Life Sciences, says flow cytometry techniques can help our understanding of cancer associated fibroblasts but there is still work to be done. Inside any solid tumour there is high heterogeneity, and the types of tumour cells,… Read More

#Exclusive Content

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Interview #Oncology #PharmEnable

Sitting down with… PharmEnable

Listen to this article on the DDW podcast: Reece Armstrong speaks to Natalia Mateu, Co-Founder, Jelena Aleksic, Co-Founder and Peter Curran, Chemoinformatics Scientist, about utilising 3D chemistry and AI to get small molecule therapies from the clinic to the bedside. RA: How is Pharmenable aiming to replicate the specificity of biologics… Read More

#Exclusive Content

Basel map
#Biologics / Biotechnology #Cancer immunotherapy #Immuno-oncology #Market reporting #Oncology #Start-ups

Basel: a centre for ground-breaking oncology 

Listen to this article on the DDW podcast: Dr Stephan Emmerth and Paul Eschmann, Basel Area Business & Innovation, explain the benefits of being based in Basel – the talent pool, global players, academic institutions and investors, for example.  Companies specialising in oncology R&D and therapeutics continue to spring up all… Read More

#Exclusive Content #Market Reports

#Collaboration #CRISPR #CRISPR-Cas9 #Cystic fibrosis #Finance #Gene editing #Liver disease #Neuropsychiatric disorders #Oncology #RNA

This week in drug discovery (10-14 October)

News round-up for 10-14 October by DDW Digital Content Editor Diana Spencer The top news in the world of drug discovery this week reflects the vital importance of collaboration, partnership and support within this industry.  Partnerships… Read More

#News

Cancer research in lab
#Cancer research #Collaboration #Genomics #Oncology

Strategic collaboration to enhance targeted oncology programmes

Oncology platform company Tavros Therapeutics and biopharmaceutical company Vividion Therapeutics (a subsidiary of Bayer AG) have agreed to collaborate on four oncology targets across an initial five-year term. Tavros’ functional and computational genomics technologies are designed to uncover unique vulnerabilities within tumours to discover novel targets and biomarkers in areas… Read More

#Business & Investment #Cancer Research #News

Breast cancer
#Breast cancer #Breast Cancer Now #Cancer immunotherapy #Cancer research #King's College London #Oncology #The Institute of Cancer Research

Immune targets identified for chemo-resistant breast cancers

Researchers from King’s College London and The Institute of Cancer Research, London, have performed a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery. The research gives insight… Read More

#Cancer Research #News

#ALS #Alzheimer's #Biomarkers #Breast cancer #Cell and gene therapy #Head and neck cancer #Ice Bucket Challenge #Manufacturing #Neurodegenerative disorders #Oncology #Ophthalmology

This week in drug discovery (3-7 October)

News round-up for 3-7 October by DDW Digital Content Editor Diana Spencer This week has brought new trial results and regulatory approvals shedding light and bringing hope into therapy areas of unmet need. The University of Birmingham and… Read More

#News

#Cancer research #Cancer Research Horizons #Cancer Research UK #Drug development #Drug discovery #Oncology

New horizon for cancer innovation

Listen to this article on the DDW podcast: Earlier this year, Cancer Research UK (CRUK) launched its innovation engine, Cancer Research Horizons, to streamline drug discovery through the combination of its commercial and therapeutics teams. Reece Armstrong sits down with Cancer Research Horizons’ Chief Business Officer, Tony Hickson and CEO of… Read More

#Cancer Research #Exclusive Content

#Biomarkers #Oncology

Study highlights importance of biomarkers in tumour progression

The University of Birmingham has published the results of a study undertaken in head and neck squamous cell carcinoma (HNSCC) by liquid biopsy company ANGLE, which characterised the epithelial-mesenchymal transition (EMT) status of circulating tumour cells (CTCs).   EMT is clinically significant due to its role in tumour… Read More

#News

#Biologics #Cell and gene therapy #Malaria #Manufacturing #Oncology

This week in drug discovery (26-30 September)

This week in drug discovery (26-30 September) News round-up by DDW Editor Reece Armstrong. An interesting week across the board for the pharma sector with the first biologic for severe asthma approved in the EU. Elsewhere researchers have discovered new ways of  identifying cancer cells and a manufacturing system could… Read More

#News

Melanoma or skin cancer
#Immuno-oncology #Melanoma #Oncology

T cell therapy for melanoma shows promise 

New trial data has shown that using a patient’s own immune cells could be a powerful immunotherapy for metastatic melanoma, an aggressive skin cancer.  The TIL (tumour-infiltrating lymphocytes) trial compared T cell therapy to standard immunotherapy with the checkpoint inhibitor ipilimumab.  The results of the… Read More

#Cancer Research #News

Herpes virus cells
#Cancer research #Cancer treatment #Herpes virus #Immunotherapy #Oncology #The Institute of Cancer Research

Researchers successfully exploit virus against advanced cancers

A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. Researchers have found that RP2 – a modified version of the herpes simplex virus – showed signs of effectiveness in a quarter of patients with a range of… Read More

#Cancer Research #News #Trending News

Breast cancer cells
#Breast cancer #Cancer research #Oncology

Breast cancer cells ‘regulate their own metastases’

Scientists have discovered a type of breast cancer cell that is highly efficient in invading and colonising distant organs and slow their growth once there to evade therapies. This phenomenon then leads to later metastatic breast cancer in patients who have been cancer-free for years. According to a study published… Read More

#Cancer Research #News

Colorectal cancer
#Cancer research #Colorectal cancer #Oncology

Trial sheds light on combined treatment for colorectal cancer

A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. Findings from the SUNLIGHT trial have revealed that the combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in overall survival compared to trifluridine/tipiracil alone. The Phase III clinical trial studied participants with… Read More

#Cancer Research #News

Professor Melief
#Cancer #Cancer research #Immunology #Immunotherapy #Oncology

ISA Pharmaceuticals’ founder recognised by SITC

Professor Dr Cornelis (‘Kees’) Melief has been awarded the 2022 Pedro J Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC).  The Award recognises individuals who have made immeasurable contributions and demonstrated outstanding commitment to the Journal for Immunotherapy of Cancer (JITC) and will be… Read More

#News